Clinical Trial Update: Evaluation of the Efficacy and Safety of QVA149 (110/50 μg o.d.) vs Tiotropium (18 µg o.d.) + Salmeterol/Fluticasone Propionate FDC (50/500 µg b.i.d.) in Patients With Moderate to Severe COPD [Phase 4]

View source ↗

Summary

Phase 4 trial comparing QVA149 to tiotropium plus salmeterol/fluticasone in moderate to severe COPD; results completed with posted data in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• QVA149 (indacaterol/glycopyrronium)
• Salmeterol/Fluticasone Propionate FDC (salmeterol/fluticasone propionate)
• tiotropium (tiotropium)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Chronic Obstructive Pulmonary Disease (COPD) | Phase 4 | Status: COMPLETED | Results posted: 2019-04-29